Unknown PHASE1 INTERVENTIONAL 1-arm NCT02921685

Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation (PIRAT)

A Phase 1 Study of MONALIZUMAB (IPH2201), a Humanized Anti CD94/NKG2A Monoclonal Antibody (Mab) Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation (SCT) Prepared With a Reduced Intensity Conditioning

Sponsor: Innate Pharma

Conditions Hematologic Malignancies

Interventions Monalizumab

Updated 7 times since 2017 Last updated: Sep 18, 2018 Started: Nov 28, 2016 Primary completion: May 28, 2019 Completion: Apr 28, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Hematologic Malignancies and is currently ongoing. Innate Pharma leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Oct 2020 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Oct 2018 — Oct 2020 [monthly]

Recruiting PHASE1

▶ Show 2 earlier versions

Jun 2018 — Oct 2018 [monthly]

Recruiting PHASE1
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Innate Pharma
Institut Paoli-Calmettes

Data source: Institut Paoli-Calmettes

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Marseille, France